| Date | Title | Description |
| 02.02.2026 | Antheia Secures $24M, Bolstering U.S. Drug Manufacturing Resilience | Antheia, a biosynthesis leader, closed its Series C financing with an additional $24 million, bringing its year-long capital securement past $175 million. This vital funding drives the expansion of U.S. pharmaceutical manufacturing capacity... |
| 27.01.2026 | Antheia Raises $24M in Second Close of Series C Financing | Antheia, a Menlo Park, CA-based biosynthesis company delivering pharmaceutical manufacturing, completed a second close of its Series C financing, raising an additional $24M.
The round was led by ATHOS KG and America’s Frontier Fund, with pa... |
| 27.01.2026 | Antheia Announces Additional $24M Series C |
MENLO PARK, CA, Antheia today announced it has completed a second close of its Series C financing, raising an additional $24 million.
>> Click here for more funding data on Antheia
>> To export Antheia funding data to PDF and E... |
| 07.07.2025 | Family offices ramp up deal-making in June with bets on biotech | After a slow spring, investment firms of the ultra-rich made 60 direct investments in June, according to Fintrx.
Family offices flocked to biotech and health-care firms such as Antheia, seeking to make an impact and returns at the same time... |
| 08.06.2025 | Antheia's $56 Million Boost: A Game Changer in Pharmaceutical Manufacturing | Antheia, a Menlo Park-based pharmaceutical ingredient manufacturer, has struck gold with its recent $56 million Series C funding round. This infusion of capital, led by the Global Health Investment Corporation (GHIC), marks a significant le... |
| 07.06.2025 | Antheia: $56 Million Series C Raised For Advancing Global Commercialization Strategy | Antheia, a pharmaceutical ingredient manufacturer transforming essential medicine supply chains, announced it has raised $56 million in Series C financing. The Series C funding round was led by Global Health Investment Corporation (GHIC), a... |
| 03.06.2025 | Antheia Inks $56M Series C Round |
MENLO PARK, CA, Antheia, the pharmaceutical ingredient manufacturer transforming essential medicine supply chains, today announced it has raised $56 million in Series C financing.
>> Click here for more funding data on Antheia
>&g... |
| 03.06.2025 | Antheia Raises $56M in Series C Funding | Antheia, a Menlo Park, CA-based pharmaceutical ingredient manufacturer, raised $56M in Series C funding.
The round wads led by Global Health Investment Corporation. Additional new investors included ATHOS KG and Federov, while existing inve... |
| 25.07.2024 | Antheia: Pharmaceutical Ingredient Producer Secures $17 Million In New Funding | Antheia, the pharmaceutical ingredient manufacturer transforming essential medicine supply chains, announced $17 million in new funding through a government project agreement through the Biopharmaceutical Manufacturing Preparedness Consorti... |
| 21.07.2024 | Antheia Raises $17M in Funding | Antheia, a Menlo Park, CA-based pharmaceutical ingredient manufacturer, raised $17M in funding.
The funding included a non-dilutive two-year project agreement up to $11M through the BioMaP Consortium and additional investment from In-Q-Tel,... |
| 19.07.2024 | Antheia Announces $17M in New Funding |
MENLO PARK, CA, Antheia, the pharmaceutical ingredient manufacturer transforming essential medicine supply chains, announced $17 million in new funding.
>> Click here for more funding data on Antheia
>> To export Antheia fundin... |
| 14.03.2024 | Antheia und Olon führen Zusammenarbeit bei der Herstellung von KSMs und APIs für unentbehrliche Medikamente aus Antheias Produktpipeline fort | Olon unterstützt Antheia bei Scale-up und Kommerzialisierung der ersten Produkte
MENLO PARK, Kalif., und MAILAND, Italien, March 14, 2024 (GLOBE NEWSWIRE) -- Der pharmazeutische Wirkstoffhersteller Antheia, der Supply Chains für essenzielle... |
| 14.03.2024 | Antheia et Olon poursuivent leur partenariat pour la biofabrication de matières premières essentielles et de principes actifs pharmaceutiques d'Antheia pour les médicaments essentiels | Olon soutiendra la poursuite de la mise à l'échelle et de la commercialisation des produits de première génération d'Antheia
MENLO PARK, Californie et MILAN, Italie, 14 mars 2024 (GLOBE NEWSWIRE) -- Antheia, le fabricant d'ingrédients pharm... |
| 13.03.2024 | Antheia et Olon poursuivent leur partenariat pour la biofabrication de matières premières essentielles et de principes actifs pharmaceutiques d'Antheia pour les médicaments essentiels | - |
| 25.08.2023 | Antheia Achieves Major Commercial Milestone | Company's first full-scale fermentation run reinforces commercial viability for a robust pipeline of Biosynthetic KSMs and APIs
MENLO PARK, Calif., Aug. 25, 2023 /PRNewswire/ -- Antheia, the pharmaceutical ingredient manufacturer transformi... |
| 28.03.2023 | 10 Women Founders Taking The Synthetic Biology World By Storm | Synthetic Biology is one of the most exciting technologies of the decade that promises to reimagine entire industries and solve the economic, societal, and environmental problems of the twenty-first century. The recent signing of the Execut... |
| 13.07.2021 | Digital health news, funding roundup week of July 12 | Osso VR secured $27M, Linus Health landed $55M; Thrive Global raised $80M
RealSleep: RealSleep is a L.A.-based company making what it says is a fully customizable, cannabinoid-based sleep aid. RealSleep has raised $2.2 million in seed fundi... |
| 06.07.2021 | Healthcare startups funding roundup week of June 28 | Sword Health raised $85M; Tendo landed $50M: ObvioHealth secured $31M
Olive: Olive is a Columbus, Oh.-based developer of health care services bots. Olive has raised $400 million in fresh funding co-led by Vista Equity Partners and Base10 Pa... |
| 01.07.2021 | Antheia Raises $73M in Series B Funding | Antheia, a Menlo Parck CA-based synthetic biology company, raised $73M in Series B funding. |
| 01.07.2021 | Antheia secures $73M | Antheia has raised a $73 million Series B led by Viking Global Investors, with participation from Sherpalo Ventures and Hillspire. The Menlo Park, Calif.-based company uses synthetic biology and fermentation technology to develop plant-base... |
| 01.07.2021 | Daily funding roundup - July 1st, 2021 | Zipline raised $250M; FightCamp secured $90M; Sword Health landed $85M
Zipline: Zipline is a San Francisco-based drone delivery startup that got its start delivering medical supplies across Africa and now sees opportunity in delivering heal... |
| 01.07.2021 | Antheia Raises $73M in Series B Funding | Antheia, a Menlo Parck CA-based synthetic biology company, raised $73M in Series B funding.
The round was led by Viking Global Investors with participation from Sherpalo Ventures and Hillspire.
The company intends to use the funds to expand... |
| 30.06.2021 | Synthetic-Biology Startup Antheia Raises $73 Million | Antheia Inc., a startup using synthetic biology to produce medicines currently sourced from plants, has raised $73 million in new venture-capital financing.
Many medications, including several analgesics and cancer treatments, are derived f... |
| 30.06.2021 | Antheia Inks $73M Series B Financing Round |
MENLO PARK, CA, Antheia, a synthetic biology company enabling next-generation plant-inspired medicines, has raised $73 million in Series B financing.
>> Click here for more funding data on Antheia
>> To export Antheia fundin... |
| 30.06.2021 | Antheia : Announces $73M Series B to Commercialize Synthetic Biology Platform for Essential Medicines | MENLO PARK, Calif., June 30, 2021 /PRNewswire/ -- Antheia, a synthetic biology company enabling next-generation plant-inspired medicines, announced today that it has raised $73M in Series B financing. The oversubscribed round was led by Vik... |
| 30.06.2021 | Can J.Crew make a comeback? | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
Paid Content Why marketers are adopting a scientific approach From Optimizely
It was not too long... |
| 30.06.2021 | Can J.Crew make a comeback? | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
It was not too long ago that its clothing was plastered across the pages of fashion and political... |
| 30.06.2021 | Antheia Announces $73M Series B to Commercialize Synthetic Biology Platform for Essential Medicines | Led by Viking Global Investors, the Series B round will be used to bring Antheia's first pharmaceutical compounds to market, expand its pipeline and scale production in global markets
MENLO PARK, Calif., June 30, 2021 /PRNewswire/ -- Anthei... |
| - | Opportunities at the Intersection of Biology, Software, and Automation | Over the past two decades, we’ve seen hundreds of billions of dollars of market capitalization created by new software and infrastructure companies built at the intersection of mobile, data, and cloud computing.
Now, we’re in the middle of... |
| - | Antheia | “Transforming pharmaceutical supply chains using synthetic biology, to end drug shortages and unlock new opportunities in development and discovery” |
